| Not Yet Recruiting | Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumo NCT07480733 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Study of TPD3310 in Patients With Advanced Malignant Tumors NCT07368127 | TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. | Phase 1 |
| Not Yet Recruiting | Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors NCT07363369 | West China Hospital | Phase 1 |
| Recruiting | JSKN022 in Subjects With Advanced Malignant Solid Tumors NCT07292402 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | A Study of CSCJC3456 in Patients With Advanced Malignant Tumors NCT06717750 | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors NCT06728189 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors NCT06499350 | FindCure Biosciences (ZhongShan) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors NCT06571422 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Recruiting | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors NCT06573294 | Genmab | Phase 1 |
| Recruiting | A Study of GQ1010 in Subjects With Advanced Solid Tumors NCT06464055 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors NCT05949775 | Stemirna Therapeutics | N/A |
| Recruiting | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors NCT05886374 | Hutchmed | Phase 1 |
| Recruiting | Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors NCT05749627 | The First Affiliated Hospital of Nanchang University | N/A |
| Completed | A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors NCT06231550 | FindCure Biosciences (ZhongShan) Co., Ltd. | Phase 1 |
| Completed | Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor NCT05383703 | Moon (Guangzhou) Biotechnology Co., Ltd. | Phase 1 |
| Unknown | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. NCT05338957 | Shanghai Miracogen Inc. | Phase 1 / Phase 2 |
| Unknown | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle In NCT05478785 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors NCT05773937 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Unknown | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT NCT05277454 | Hutchison Medipharma Limited | Phase 1 |
| Completed | A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors NCT04908046 | Hutchmed | Phase 1 |
| Completed | Bioequivalency Study of CM082 Tablet in Healthy Volunteers NCT04328506 | AnewPharma | Phase 1 |
| Completed | A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers NCT04126668 | AnewPharma | Phase 1 |
| Unknown | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T6 NCT04226066 | Tasly Tianjin Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors NCT03792958 | AnewPharma | Phase 1 |
| Unknown | The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced NCT03047811 | Fudan University | N/A |
| Terminated | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors NCT02045095 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor NCT01128842 | Puma Biotechnology, Inc. | Phase 1 |
| Withdrawn | Study of PKI-179 Administered Orally to Subjects With Solid Tumors NCT00997360 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumor NCT00958724 | Puma Biotechnology, Inc. | Phase 1 |
| Completed | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors NCT00884845 | PharmaMar | Phase 1 |
| Completed | Study Evaluating Safety And Tolerability, Solid Tumor NCT00768469 | Puma Biotechnology, Inc. | Phase 1 |
| Completed | A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients NCT00728468 | Pfizer | Phase 1 |
| Completed | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metasta NCT00706030 | Puma Biotechnology, Inc. | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors NCT00445458 | Puma Biotechnology, Inc. | Phase 1 / Phase 2 |